2-chloro-5-hydroxy-[1,1’-biphenyl]-4-carboxylic acid | 2230807-84-6

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 2-chloro-5-hydroxy-[1,1’-biphenyl]-4-carboxylic acid
• 英文别名: 5-Chloro-2-hydroxy-4-phenylbenzoic acid
• CAS: 2230807-84-6
• 化学式: C₁₃H₉ClO₃
• 分子量: 248.666
• InChiKey: XGEAIFNIEJXMGH-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4.4
• 重原子数：
  17
• 可旋转键数：
  2
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  57.5
• 氢给体数：
  2
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  2-chloro-5-hydroxy-[1,1’-biphenyl]-4-carboxylic acid 在 氯化亚砜 、 N,N-二甲基甲酰胺 作用下， 以 二氯甲烷 为溶剂， 反应 12.0h， 生成
  参考文献：
  名称：

  SAR optimization studies on modified salicylamides as a potential treatment for acute myeloid leukemia through inhibition of the CREB pathway

  摘要：

  Disruption of cyclic adenosine monophosphate response element binding protein (CREB) provides a potential new strategy to address acute leukemia, a disease associated with poor prognosis, and for which conventional treatment options often carry a significant risk of morbidity and mortality. We describe the structure-activity relationships (SAR) for a series of XX-650-23 derived from naphthol AS-E phosphate that disrupts binding and activation of CREB by the CREB-binding protein (CBP). Through the development of this series, we identified several salicylamides that are potent inhibitors of acute leukemia cell viability through inhibition of CREB-CBP interaction. Among them, a biphenyl salicylamide, compound 71, was identified as a potent inhibitor of CREB-CBP interaction with improved physicochemical properties relative to previously described derivatives of naphthol AS-E phosphate.

  DOI：

  10.1016/j.bmcl.2019.06.023
• 作为产物：
  描述：

  2-chloro-5-methoxy-[1,1'-biphenyl]-4-carboxylic acid 在 三溴化硼 作用下， 以 二氯甲烷 为溶剂， 反应 1.5h， 以97%的产率得到2-chloro-5-hydroxy-[1,1’-biphenyl]-4-carboxylic acid
  参考文献：
  名称：

  [EN] STAT3 TRANSCRIPTION FACTOR INHIBITORS AND METHODS OF USING THE SAME
  [FR] INHIBITEURS DU FACTEUR DE TRANSCRIPTION STAT3 ET LEURS PROCÉDÉS D'UTILISATION

  摘要：

  公开号：

  WO2020118265A3

文献信息

• STAT3 TRANSCRIPTION FACTOR INHIBITORS AND METHODS OF USING THE SAME
  申请人：REIGAN Philip

  公开号：US20220017476A1

  公开（公告）日：2022-01-20

  Compounds that inhibit the activity of Signal transducer and activator of transcription 3 (STAT3), or pharmaceutically acceptable salts or prodrugs thereof, and methods of using these compounds to treat cancer and other diseases.